Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2'-deoxyguanosine in forensic autopsy cases.

Kashiwagi M, Sugimura T, Matsusue A, Hara K, Waters B, Kubo S.

Leg Med (Tokyo). 2013 May;15(3):140-4. doi: 10.1016/j.legalmed.2012.11.001. Epub 2012 Dec 25.

PMID:
23273867
2.

Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K.

Mol Cell Biochem. 2006 Mar;284(1-2):175-82. Erratum in: Mol Cell Biochem. 2007 May;299(1-2):1-3.

PMID:
16532260
3.

Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.

Mou S, Wang Q, Li J, Shi B, Ni Z.

Clin Chim Acta. 2012 Jan 18;413(1-2):187-91. doi: 10.1016/j.cca.2011.09.018. Epub 2011 Sep 17.

PMID:
21958699
4.

Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease.

Fukuda Y, Miura S, Zhang B, Iwata A, Kawamura A, Nishikawa H, Shirai K, Saku K.

Intern Med. 2009;48(19):1731-7. Epub 2009 Oct 1.

5.

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.

Manabe K, Kamihata H, Motohiro M, Senoo T, Yoshida S, Iwasaka T.

Eur J Clin Invest. 2012 May;42(5):557-63. doi: 10.1111/j.1365-2362.2011.02620.x. Epub 2011 Nov 10.

PMID:
22070248
7.

Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.

Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H.

Metabolism. 2009 Aug;58(8):1185-90. doi: 10.1016/j.metabol.2009.03.019. Epub 2009 Jun 18.

PMID:
19481229
8.

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

Diabetes Care. 2005 Nov;28(11):2728-32.

PMID:
16249547
9.

Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.

Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF.

Nephrol Dial Transplant. 2008 Oct;23(10):3160-5. doi: 10.1093/ndt/gfn190. Epub 2008 Apr 10.

10.

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.

Am J Hypertens. 2007 Nov;20(11):1195-201.

PMID:
17954367
11.

Urinary neutrophil gelatinase-associated lipocalin and L-type fatty acid binding protein as diagnostic markers of early acute kidney injury after liver transplantation.

Li Y, Zhu M, Xia Q, Wang S, Qian J, Lu R, Che M, Dai H, Wu Q, Ni Z, Lindholm B, Axelsson J, Yan Y.

Biomarkers. 2012 Jun;17(4):336-42. doi: 10.3109/1354750X.2012.672458. Epub 2012 Mar 29.

PMID:
22455661
12.

Urinary L-FABP and its combination with urinary NGAL in early diagnosis of acute kidney injury after cardiac surgery in adult patients.

Liu S, Che M, Xue S, Xie B, Zhu M, Lu R, Zhang W, Qian J, Yan Y.

Biomarkers. 2013 Feb;18(1):95-101. doi: 10.3109/1354750X.2012.740687. Epub 2012 Nov 21.

PMID:
23167703
13.

Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia.

Yang Y, Tian Y, Yan C, Jin X, Tang J, Shen X.

Environ Toxicol. 2009 Oct;24(5):446-52. doi: 10.1002/tox.20447.

PMID:
18979530
14.

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Nakamura T, Sugaya T, Node K, Ueda Y, Koide H.

Am J Kidney Dis. 2006 Mar;47(3):439-44.

PMID:
16490622
15.

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.

von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM.

Eur J Clin Invest. 2010 Feb;40(2):95-102. doi: 10.1111/j.1365-2362.2009.02220.x. Epub 2009 Nov 11.

PMID:
19912308
16.

A newly developed kit for the measurement of urinary liver-type fatty acid-binding protein as a biomarker for acute kidney injury in patients with critical care.

Sato R, Suzuki Y, Takahashi G, Kojika M, Inoue Y, Endo S.

J Infect Chemother. 2015 Mar;21(3):165-9. doi: 10.1016/j.jiac.2014.10.017. Epub 2014 Nov 18.

PMID:
25499195
17.

Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery.

Katagiri D, Doi K, Honda K, Negishi K, Fujita T, Hisagi M, Ono M, Matsubara T, Yahagi N, Iwagami M, Ohtake T, Kobayashi S, Sugaya T, Noiri E.

Ann Thorac Surg. 2012 Feb;93(2):577-83. doi: 10.1016/j.athoracsur.2011.10.048.

PMID:
22269724
18.

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.

Am J Med Sci. 2007 Jun;333(6):321-6.

PMID:
17570983
19.

Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).

Inoue T, Ikeda H, Nakamura T, Abe S, Taguchi I, Kikuchi M, Toyoda S, Miyazono M, Kishi T, Sanai T, Node K.

Intern Med. 2011;50(12):1273-8. Epub 2011 Jun 15.

20.

Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K.

Diabetes Care. 2011 Mar;34(3):691-6. doi: 10.2337/dc10-1392. Epub 2011 Jan 27.

Items per page

Supplemental Content

Write to the Help Desk